1. Home
  2. AKBA vs XNET Comparison

AKBA vs XNET Comparison

Compare AKBA & XNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.92

Market Cap

343.4M

Sector

Health Care

ML Signal

HOLD

Logo Xunlei Limited

XNET

Xunlei Limited

HOLD

Current Price

$5.06

Market Cap

358.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
XNET
Founded
2007
2003
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
343.4M
358.4M
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
AKBA
XNET
Price
$0.92
$5.06
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.67
N/A
AVG Volume (30 Days)
4.8M
248.1K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.29
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$4.52
52 Week High
$3.22
$11.03

Technical Indicators

Market Signals
Indicator
AKBA
XNET
Relative Strength Index (RSI) 36.55 45.97
Support Level $0.85 $4.80
Resistance Level $1.54 $5.25
Average True Range (ATR) 0.06 0.20
MACD -0.01 -0.00
Stochastic Oscillator 17.30 46.62

Price Performance

Historical Comparison
AKBA
XNET

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

Share on Social Networks: